qRT-PCR

Life Technologies offers 2 TaqMan® qPCR grants

by Christoph on October 5, 2011

in News

Life Technologies has 2 TaqMan® qPCR consumables grants available for European research teams*. You have the opportunity to make your project come to life with a grant of either 10,000 or 5,000 euros*.

To apply for the grant you will need to tell Life Technologies about a specific challenge you would like to tackle, what you aim to achieve and outline your motivation for pursuing your study.

Applications will be accepted for a very limited time. Pre-registration is open now. If you would like to pre-register for the TaqMan® Grant please visit www.taqmangrant.com

*Please see Terms and Conditions, available on the TaqMan® Grant website for country eligibility and further details.

Incoming search terms for this article:

{ 0 comments }

PrimeraDx Launches the Only System Capable of Simultaneous Quantification of mRNA, microRNA and DNA

by Christoph on August 23, 2011

in Press Release

MANSFIELD, Mass., Aug. 23, 2011 /PRNewswire/ — PrimeraDx today announced the launch of the ICEPlex® system, the only instrument on the market used for simultaneous detection and quantification of disparate target types, such as mRNA, miRNA, SNPs and DNA“We are excited to have launched the ICEPlex, a quantitative multiplex PCR platform,” stated President and CEO Matthew McManus, MD, PhD.   “No longer will users have to rely on semi-quantitative multiplex solutions.  The ability to take one slice of tissue, extract the nucleic acids, and in one well, in parallel, look at mRNA expression, microRNA expression and SNPs is very powerful.”

PrimeraDx has developed an open platform enabling clinical labs to easily develop cost-effective, high impact molecular diagnostic tests.  The ICEPlex instrument has already been placed with a number of key accounts, including large academic research centers, reference laboratories and bio-pharmaceutical companies.   The ICEPlex instrument has a simple workflow and comes with on-board software for assay design, data analysis and reporting.

“It is very exciting to have this innovative platform from PrimeraDx.  As far as I know, this is the only platform that allows you to assay multiple target types, like mRNA, miRNA and SNPs, in a single well,” commented Andrew Schade, MD, PhD, Senior Director of [click to continue…]

Incoming search terms for this article:

{ 0 comments }

Outsourcing your RNA

by Chris on September 30, 2010

in Publications

RNA expression analysis can be acomplished by microarrays, next-gen sequencing, in situ hybridization or qRT-PCR, but not all investigators have these capabilities in their own labs. Whether constrained by space, infrastructure, know-how, or time, many have no choice but to outsource these types of analyses to others. Often, that means employing a university core facility. But some elect to go off campus altogether, enlisting commercial service providers instead.  Here are some accounts of outsourcing experiences by a few RNA researchers. (read more… )

{ 0 comments }

MicroRNAs as Potential Biomarkers in Cancer and Heart Disease

by Chris on October 30, 2009

in Technical Article

Heart disease and cancer represent the number one and number two killer diseases in developed countries. Identifying biomarkers to detect these and other diseases at early stages remains an important research goal and researchers are scrambling for ways to identify contributing factors to the pathogenesis of diseased cells in the body.  In recent years, research has turned to the study of microRNA (miRNA) as possible biomarkers due to their extensive role in biological processes and cell functionality in normal vs. diseased cells.  Microarrays combined with quantitative real-time PCR (qRT-PCR) validation are proving to be valuable tools for miRNA expression profiling and are predicted to play a crucial role in biomarker discovery and detection.  [click to continue…]

Incoming search terms for this article:

{ 0 comments }

qPCR Congress 2009

by Christoph on April 29, 2009

in Conferences

During a recent analyst briefing titled “From Stem Cells and Cancer to Diagnostics and Therapeutics; microRNAs-Small Molecules with a Big Impact” Frost & Sullivan presented data about the US miRNA market. According to these data the qRT-PCR segment represents the largest segment in the overall miRNA market (37.7%). It is followed by the microarray segment which accounts for 30.4%.

Considering the importance of qRT-PCR in our field the following conference announcement might be of interest:
qPCR Congress 2009 (www.qpcr-congress.com), is to be held on the 16th & 17th November in London. The congress is the single most focused event in Europe dedicated to key technological and scientific trends & advances in qPCR in the pharmaceutical and biotech industry, as well as academic institutions. Over two days, the organizers expect over 120 senior-level decision makers working in discovery, biomarkers, gene expression, molecular biology, and clinical & diagnostics development and bioinformatics & data management from the UK, Europe and US. For more information please contact info@oxfordglobal.co.uk

{ 0 comments }